RPH-002 (цетуксимаб)
Проводит АО «Р-Фарм»
Страница компанииОткрытое, рандомизированное, многоцентровое сравнительное исследование фармакокинетики, безопасности и эффективности препаратов RPH-002 и Эрбитукс® у пациентов с неоперабельным метастатическим или рецидивирующим плоскоклеточным раком головы и шеи
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/557/2018-11-06/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 50 чел. в стране «Россия».
- Центров в реестре: 18 в 13 городах. Список — ниже на странице.
- Плановая дата окончания (12.2022) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Индекс Карновскогоне ниже 70%
- Предшествующее лечениепосле предшествующей терапии (рецидив или прогрессия)
- Биомаркеры в критерияхEGFR
- Опухольнужен измеримый очаг (RECIST)
- Стадияметастатическая (IV)
- Индекс массы тела18–30 кг/м²
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 33 · невключение: 29
Критерии включения
- Main Period (Period 1)
- A voluntarily signed and dated Informed Consent form (ICF) of the patient
- Histologically confirmed squamous cell carcinoma of the head and neck
- Body mass index (BMI) between 18 and 30 kg/m\^2, inclusive
- Documented unresectable locoregional recurrence or distant metastases, or progression after prior chemoradiotherapy or combination therapy completed >3 months before screening, not amenable to local treatment (except cases with high risk of tumor lysis or bleeding), or newly diagnosed metastatic disease not previously treated with systemic therapy. Study treatment is first-line therapy
- At least one measurable lesion per RECIST 1.1
- Karnofsky performance status ≥70%
- Screening laboratory values within the following limits (per local lab normal ranges):
- Hemoglobin ≥90 g/L
- Leukocytes ≥3.0 × 10\^9/L
- Neutrophils ≥1.5 × 10\^9/L
- Platelets ≥100 × 10\^9/L
- Total bilirubin ≤2 × Upper Limit of Normal (ULN)
- Aspartate aminotransferase (AST) ≤3 × ULN
- Alanine aminotransferase (ALT) ≤3 × ULN
- Estimated glomerular filtration rate (eGFR) ≥60 mL/min
- Men and women of childbearing potential, and women within 2 years of menopause, must agree to use reliable contraception from informed consent through at least 6 months after study treatment; women of childbearing potential must have a negative urine pregnancy test. Women with no reproductive potential (≥2 years post-menopause or surgically sterile) are exempt
- Ability and willingness to comply with study protocol and procedures for the planned duration of participation
- Ability to undergo required pharmacokinetic sample collection, as judged by the investigator
- Maintenance Therapy Period (Period 2)
- Documented tumor response or disease stabilization per RECIST 1.1 by computed tomography (CT) or magnetic resonance imaging (MRI) at Week 18 of the Main Period
- Ability and willingness to provide written informed consent for participation in Period 2
- Karnofsky performance status ≥ 70%
- Laboratory values within the following limits (per local lab normal ranges):
- Hemoglobin ≥ 90 g/L
- Leukocytes ≥ 3.0 × 10\^9/L
- Neutrophils ≥ 1.5 × 10\^9/L
- Platelets ≥ 100 × 10\^9/L
- Total bilirubin ≤ 2 × ULN (upper limit of normal)
- AST ≤ 3 × ULN
- ALT ≤ 3 × ULN
- eGFR ≥ 60 mL/min
- Men and women of childbearing potential, and women within 2 years of menopause, must agree to use reliable contraception from informed consent through at least 6 months after study treatment; women of childbearing potential must have a negative urine pregnancy test. Women with no reproductive potential (≥2 years post-menopause or surgically sterile) are exempt
Критерии невключения
- Main Period (Period 1)
- Prior therapy with cetuximab or other monoclonal antibody-based biologics
- Chemotherapy, radiotherapy, or surgery for head and neck cancer within 3 months before screening
- Any other surgery (except biopsy, implantable venous port placement, or urgent non-cancer surgery) within 3 months before screening
- Nasopharyngeal carcinoma
- Other malignancy within the past 5 years or prior/concurrent squamous cell carcinoma (except cured in situ ductal carcinoma, cervical carcinoma in situ, basal cell or squamous cell skin cancer)
- Expected survival < 3 months
- Women who are pregnant or breastfeeding, or unwilling to use effective contraception during the study and for at least 6 months after
- Significant cardiovascular disease per investigator, including uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥130 mmHg), coronary artery disease, myocardial infarction within 12 months, high-risk uncontrolled arrhythmias, or uncontrolled heart failure
- Active infection requiring systemic antibiotic therapy
- Ongoing systemic immunotherapy, hormone therapy, or other cancer treatments not specified in the protocol within 6 months prior to screening or during the study
- Known or suspected brain metastases, including parenchymal, leptomeningeal, or dural involvement associated with symptoms
- Positive screening for HBsAg, anti-HCV, anti-HIV1/2 antibodies, or syphilis within 3 months prior to screening
- Conditions preventing compliance with the study protocol per investigator
- Participation in another investigational drug study within 6 months prior to screening
- Unstable medical conditions, including uncontrolled diabetes, psychiatric disorders, or uncontrolled seizures, that could interfere with protocol adherence
- Known hypersensitivity to any component of study therapy or combination chemotherapy drugs
- Excessive alcohol use (>10 standard drinks/week) or history of alcoholism or substance abuse associated with symptoms. One standard drink = 250 mL beer, 125 mL wine, or 30 mL spirits
- Maintenance Therapy Period (Period 2)
- No documented tumor response or disease stabilization per RECIST 1.1 by CT or MRI at Week 18 of the Main Period
- Women who are pregnant or breastfeeding, or unwilling to use effective contraception during the study and for at least 6 months after
- Significant cardiovascular disease per investigator, including uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥130 mmHg), coronary artery disease, myocardial infarction within 12 months, high-risk uncontrolled arrhythmias, or uncontrolled heart failure
- Active infection requiring systemic antibiotics
- Ongoing systemic immunotherapy, hormone therapy, or other cancer treatments not specified in the protocol for Period 2
- Known or suspected brain metastases, including parenchymal, leptomeningeal, or dural involvement associated with symptoms
- Conditions preventing compliance with study procedures per investigator
- Participation in another investigational drug study
- Unstable medical conditions, including uncontrolled diabetes, psychiatric disorders, or uncontrolled seizures, that could interfere with protocol adherence
- Excessive alcohol use (>10 standard drinks/week) or history of alcoholism or substance abuse associated with symptoms. One standard drink = 250 mL beer, 125 mL wine, or 30 mL spirits
Источник: ClinicalTrials.gov, NCT07435311 · запись обновлена в реестре 14 июля 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 12
- Area under the pharmacokinetic curve "concentration-time" (AUC(0-168)) of cetuximab — Pre-dose on Day 1 (first administration) and 1, 2, 3, 4, 6, 12, 24, 48, 96, 168 hours post-dose
- Proportion of patients (%) with adverse drug reactions (ADRs) of any severity — Up to Day 365
Цель исследования
The primary objective of this clinical study is to compare the pharmacokinetic parameters of drugs RPH-002 and Erbitux® after a single intravenous administration, as well as to evaluate the safety of drug RPH-002 in comparison with drug Erbitux® when used in combination with Docetaxel and Cisplatin as first-line therapy in patients with Recurrent Head and Neck Squamous Cell Carcinoma. In addition, this study will include a comparative assessment of immunogenicity and a pilot evaluation of efficacy
Области и заболевания
Где проходит
18 центров в 13 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 557 от 06.11.2018 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07435311 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
Расчёт Клиномира По датам из реестраСтатус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.